A
ALX Oncology Holdings Inc. (ALXO)
NMS – Real Time Price. Currency in USD
2.04
+0.25 (13.97%)
At close: Jun 26, 2026, 4:00 PM EDT
2.00
-0.04 (-1.96%)
After-hours: Jun 26, 2026, 7:13 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NMS – Real Time Price. Currency in USD
2.04
+0.25 (13.97%)
At close: Jun 26, 2026, 4:00 PM EDT
2.00
-0.04 (-1.96%)
After-hours: Jun 26, 2026, 7:13 PM EDT
No Data
There are no news for this stock.
Company's cash reserves $32.3M significantly exceed its total debt $13.0M, ensuring strong financial flexibility
Total current assets $145.6M exceed Total current liabilities $20.2M, highlighting excellent liquidity
Debt-to-equity ratio (0.1) is well below the industry average (0.3), showcasing prudent financial management
Interest coverage ratio (-57.3x) is dangerously low, suggesting debt repayment risks
Negative free cash flow -$18.7M limits the company's ability to reinvest or pay down debt
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 7.21 | 6.05 | 10 | |
| Quick ratio | 7.21 | 5.63 | 10 | |
| Debt to Equity | 0.09 | 0.30 | 9.0 | |
| Debt to Assets | 0.07 | 1.04 | 9.0 | |
| Interest coverage | -57.30 | -16.91 | 1.0 | |
| Weighted average score | 7.8 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | -1M | -836K | -872K | -706K | -645K |
| Operating Income | -127M | -170M | -142M | -101M | -88M |
| Net Income | -123M | -161M | -135M | -102M | -89M |
| EBITDA | -126M | -169M | -142M | -100M | -87M |
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Gross margin % | N/A | -11.73 | 1.0 | |
| Operating margin % | N/A | -24.60 | 1.0 | |
| Net margin % | N/A | -172.20 | 1.0 | |
| EBITDA margin % | N/A | -201.27 | 1.0 | |
| Cash flow margin % | N/A | -156.39 | 1.0 | |
| Weighted average score | 1.0 | |||
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | N/A | 70.83 | 5.5 |
| Next quarter | N/A | 63.93 | 5.5 |
| Current year | N/A | 67.72 | 5.5 |
| Next year | N/A | 5.73 | 3.0 |
| Weighted average score | 4.9 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | 999 | 21.54 | 59.52 | 1.74 | 8.3 |
| Y/Y | 999 | 41.71 | 70.69 | 24.37 | 10 |
| 3y average | 999 | 3.5 | 11.32 | -2.36 | 5.5 |
| 5y average | 779.2 | -23.97 | 2.52 | -23.66 | 4.0 |
| Weighted average score | 7.0 | ||||
Insufficient positive free cash flow for DCF analysis
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
Insufficient positive free cash flow for DCF analysis
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | None | 1.0 |
| Intangible assets | None | 1.0 |
| Switching costs | None | 1.0 |
| Network effect | None | 1.0 |
| Economies of scale | None | 1.0 |
| Weighted average score | 1.0 | |